Table 4.
Risk Factors for Invasive Yeast Infection from D0 to D30 after Haploidentical HCT.
| Variable | No Early IYI n = 192 | Early IYI n = 13 | Univariate HR (95% CI) | Univariate P-value | Multivariable HR (95% CI) | Multivariable P-value |
|---|---|---|---|---|---|---|
| Age >55 | 100 | 8 | 1.02 (0.98 – 1.06) | 0.334 | 1.01 (0.97 – 1.04) | 0.748 |
| Male Sex | 112 | 8 | 1.56 (0.48 – 5.05) | 0.462 | 1.38 (0.42 – 4.57) | 0.597 |
| Underlying Disease | ||||||
| AML | 71 | 10 | 5.29 (1.46 – 19.24) | 0.005 | 6.24 (1.66 – 23.37) | 0.007 |
| MDS/MPN | 45 | 1 | 0.28 (0.04 – 2.19) | 0.227 | - | - |
| ALL | 20 | 1 | 0.73 (0.09 – 5.58) | 0.758 | - | - |
| HL | 8 | 1 | 1.87 (0.24 – 14.38) | 0.548 | - | - |
| Prior HCT | 25 | 4 | 2.85 (0.88 – 9.27) | 0.081 | 3.00 (0.89 – 10.14) | 0.077 |
| Graft source | ||||||
| Peripheral Blood | 91 | 9 | 1.43 (0.75 – 7.90) | 0.139 | - | - |
| Bone Marrow | 101 | 4 | 1.00 | - | - | - |
| Conditioning | ||||||
| MAC | 47 | 4 | 1.37 (0.42 – 4.45) | 0.600 | - | - |
| RIC | 145 | 9 | 1.00 | - | - | |
| CRS Diagnosis | 99 | 11 | 4.99 (1.11 – 22.53) | 0.036 | 4.65 (1.00 – 21.58) | 0.049 |
| Tocilizumab | 23 | 6 | 5.61 (1.88 – 16.69) | 0.002 | - | - |